Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy.

The Journal of experimental medicine

Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, Miles B, Farias E, Mezei M, Nobre AR, Singh D, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA.
PMID: 34812843
J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20210836. Epub 2021 Nov 23.

We describe the discovery of an agonist of the nuclear receptor NR2F1 that specifically activates dormancy programs in malignant cells. The agonist led to a self-regulated increase in NR2F1 mRNA and protein and downstream transcription of a novel dormancy...

Cite
Khalil BD, Sanchez R, Rahman T, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2021;219(1)doi: 10.1084/jem.20210836.
Khalil, B. D., Sanchez, R., Rahman, T., Rodriguez-Tirado, C., Moritsch, S., Martinez, A. R., Miles, B., Farias, E., Mezei, M., Nobre, A. R., Singh, D., Kale, N., Sproll, K. C., Sosa, M. S., & Aguirre-Ghiso, J. A. (2022). An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. The Journal of experimental medicine, 219(1), . https://doi.org/10.1084/jem.20210836
Khalil, Bassem D, et al. "An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy." The Journal of experimental medicine vol. 219,1 (2022). doi: https://doi.org/10.1084/jem.20210836
Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, Miles B, Farias E, Mezei M, Nobre AR, Singh D, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20210836. Epub 2021 Nov 23. PMID: 34812843; PMCID: PMC8614154.
Copy Download .nbib Format: NLM
MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21.

Oncotarget

Mei AH, Tung K, Han J, Perumal D, Laganà A, Keats J, Auclair D, Chari A, Jagannath S, Parekh S, Cho HJ.
PMID: 32133047
Oncotarget. 2020 Feb 18;11(7):727-739. doi: 10.18632/oncotarget.27488. eCollection 2020 Feb 18.

The type I Melanoma Antigen Gene (MAGE) A3 is a functional target associated with survival and proliferation in multiple myeloma (MM). To investigate the mechanisms of these oncogenic functions, we performed gene expression profiling (GEP) of p53 wild-type human...

Cite
Mei AH, Tung K, Han J, et al. MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21. Oncotarget. 2020;11(7):727-739doi: 10.18632/oncotarget.27488.
Mei, A. H., Tung, K., Han, J., Perumal, D., Laganà, A., Keats, J., Auclair, D., Chari, A., Jagannath, S., Parekh, S., & Cho, H. J. (2020). MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21. Oncotarget, 11(7), 727-739. https://doi.org/10.18632/oncotarget.27488
Mei, Anna Huo-Chang, et al. "MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21." Oncotarget vol. 11,7 (2020): 727-739. doi: https://doi.org/10.18632/oncotarget.27488
Mei AH, Tung K, Han J, Perumal D, Laganà A, Keats J, Auclair D, Chari A, Jagannath S, Parekh S, Cho HJ. MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21. Oncotarget. 2020 Feb 18;11(7):727-739. doi: 10.18632/oncotarget.27488. eCollection 2020 Feb 18. PMID: 32133047; PMCID: PMC7041939.
Copy Download .nbib Format: NLM
Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of .

Frontiers in cell and developmental biology

Papa L, Djedaini M, Martin TC, Zangui M, Beaumont KG, Sebra R, Parsons R, Schaniel C, Hoffman R.
PMID: 33384995
Front Cell Dev Biol. 2020 Dec 15;8:592348. doi: 10.3389/fcell.2020.592348. eCollection 2020.

No abstract available.

Cite
Papa L, Djedaini M, Martin TC, et al. Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of . Front Cell Dev Biol. 2020;8:592348doi: 10.3389/fcell.2020.592348.
Papa, L., Djedaini, M., Martin, T. C., Zangui, M., Beaumont, K. G., Sebra, R., Parsons, R., Schaniel, C., & Hoffman, R. (2020). Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of . Frontiers in cell and developmental biology, 8592348. https://doi.org/10.3389/fcell.2020.592348
Papa, Luena, et al. "Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of ." Frontiers in cell and developmental biology vol. 8 (2020): 592348. doi: https://doi.org/10.3389/fcell.2020.592348
Papa L, Djedaini M, Martin TC, Zangui M, Beaumont KG, Sebra R, Parsons R, Schaniel C, Hoffman R. Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of . Front Cell Dev Biol. 2020 Dec 15;8:592348. doi: 10.3389/fcell.2020.592348. eCollection 2020. PMID: 33384995; PMCID: PMC7769876.
Copy Download .nbib Format: NLM
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.

Journal of the National Cancer Institute

Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G, Bentzen SM, Janelsins M, Elliott RM, Pharoah PDP, Burnet NG, Dearnaley DP, Gulliford SL, Hall E, Sydes MR, Aguado-Barrera ME, Gómez-Caamaño A, Carballo AM, Peleteiro P, Lobato-Busto R, Stock R, Stone NN, Ostrer H, Usmani N, Singhal S, Tsuji H, Imai T, Saito S, Eeles R, DeRuyck K, Parliament M, Dunning AM, Vega A, Rosenstein BS, West CML.
PMID: 31095341
J Natl Cancer Inst. 2020 Feb 01;112(2):179-190. doi: 10.1093/jnci/djz075.

BACKGROUND: A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies.METHODS: We conducted an individual patient...

Cite
Kerns SL, Fachal L, Dorling L, et al. Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. J Natl Cancer Inst. 2020;112(2):179-190doi: 10.1093/jnci/djz075.
Kerns, S. L., Fachal, L., Dorling, L., Barnett, G. C., Baran, A., Peterson, D. R., Hollenberg, M., Hao, K., Narzo, A. D., Ahsen, M. E., Pandey, G., Bentzen, S. M., Janelsins, M., Elliott, R. M., Pharoah, P. D. P., Burnet, N. G., Dearnaley, D. P., Gulliford, S. L., Hall, E., Sydes, M. R., Aguado-Barrera, M. E., Gómez-Caamaño, A., Carballo, A. M., Peleteiro, P., Lobato-Busto, R., Stock, R., Stone, N. N., Ostrer, H., Usmani, N., Singhal, S., Tsuji, H., Imai, T., Saito, S., Eeles, R., DeRuyck, K., Parliament, M., Dunning, A. M., Vega, A., Rosenstein, B. S., & West, C. M. L. (2020). Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 112(2), 179-190. https://doi.org/10.1093/jnci/djz075
Kerns, Sarah L, et al. "Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy." Journal of the National Cancer Institute vol. 112,2 (2020): 179-190. doi: https://doi.org/10.1093/jnci/djz075
Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G, Bentzen SM, Janelsins M, Elliott RM, Pharoah PDP, Burnet NG, Dearnaley DP, Gulliford SL, Hall E, Sydes MR, Aguado-Barrera ME, Gómez-Caamaño A, Carballo AM, Peleteiro P, Lobato-Busto R, Stock R, Stone NN, Ostrer H, Usmani N, Singhal S, Tsuji H, Imai T, Saito S, Eeles R, DeRuyck K, Parliament M, Dunning AM, Vega A, Rosenstein BS, West CML. Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. J Natl Cancer Inst. 2020 Feb 01;112(2):179-190. doi: 10.1093/jnci/djz075. PMID: 31095341; PMCID: PMC7019089.
Copy Download .nbib Format: NLM
ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs.

Journal of neuroscience methods

Barretto N, Zhang H, Powell SK, Fernando MB, Zhang S, Flaherty EK, Ho SM, Slesinger PA, Duan J, Brennand KJ.
PMID: 32065989
J Neurosci Methods. 2020 Feb 14;334:108548. doi: 10.1016/j.jneumeth.2019.108548. Epub 2020 Feb 14.

BACKGROUND: Somatic cell reprogramming is routinely used to generate donor-specific human induced pluripotent stem cells (hiPSCs) to facilitate studies of disease in a human context. The directed differentiation of hiPSCs can generate large quantities of patient-derived cells; however, such...

Cite
Barretto N, Zhang H, Powell SK, et al. ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs. J Neurosci Methods. 2020;334:108548doi: 10.1016/j.jneumeth.2019.108548.
Barretto, N., Zhang, H., Powell, S. K., Fernando, M. B., Zhang, S., Flaherty, E. K., Ho, S. M., Slesinger, P. A., Duan, J., & Brennand, K. J. (2020). ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs. Journal of neuroscience methods, 334108548. https://doi.org/10.1016/j.jneumeth.2019.108548
Barretto, Natalie, et al. "ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs." Journal of neuroscience methods vol. 334 (2020): 108548. doi: https://doi.org/10.1016/j.jneumeth.2019.108548
Barretto N, Zhang H, Powell SK, Fernando MB, Zhang S, Flaherty EK, Ho SM, Slesinger PA, Duan J, Brennand KJ. ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs. J Neurosci Methods. 2020 Feb 14;334:108548. doi: 10.1016/j.jneumeth.2019.108548. Epub 2020 Feb 14. PMID: 32065989; PMCID: PMC7426253.
Copy Download .nbib Format: NLM
An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy.

The Journal of experimental medicine

Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, Miles B, Farias E, Mezei M, Nobre AR, Singh D, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA.
PMID: 34812843
J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20210836. Epub 2021 Nov 23.

We describe the discovery of an agonist of the nuclear receptor NR2F1 that specifically activates dormancy programs in malignant cells. The agonist led to a self-regulated increase in NR2F1 mRNA and protein and downstream transcription of a novel dormancy...

Cite
Khalil BD, Sanchez R, Rahman T, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2021;219(1)doi: 10.1084/jem.20210836.
Khalil, B. D., Sanchez, R., Rahman, T., Rodriguez-Tirado, C., Moritsch, S., Martinez, A. R., Miles, B., Farias, E., Mezei, M., Nobre, A. R., Singh, D., Kale, N., Sproll, K. C., Sosa, M. S., & Aguirre-Ghiso, J. A. (2022). An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. The Journal of experimental medicine, 219(1), . https://doi.org/10.1084/jem.20210836
Khalil, Bassem D, et al. "An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy." The Journal of experimental medicine vol. 219,1 (2022). doi: https://doi.org/10.1084/jem.20210836
Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, Miles B, Farias E, Mezei M, Nobre AR, Singh D, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20210836. Epub 2021 Nov 23. PMID: 34812843; PMCID: PMC8614154.
Copy Download .nbib Format: NLM
Genetic pleiotropy of ERCC6 loss-of-function and deleterious missense variants links retinal dystrophy, arrhythmia, and immunodeficiency in diverse ancestries.

Human mutation

Forrest IS, Chaudhary K, Vy HMT, Bafna S, Kim S, Won HH, Loos RJF, Cho J, Pasquale LR, Nadkarni GN, Rocheleau G, Do R.
PMID: 34005834
Hum Mutat. 2021 Aug;42(8):969-977. doi: 10.1002/humu.24220. Epub 2021 May 31.

Biobanks with exomes linked to electronic health records (EHRs) enable the study of genetic pleiotropy between rare variants and seemingly disparate diseases. We performed robust clinical phenotyping of rare, putatively deleterious variants (loss-of-function [LoF] and deleterious missense variants) in...

Cite
Forrest IS, Chaudhary K, Vy HMT, et al. Genetic pleiotropy of ERCC6 loss-of-function and deleterious missense variants links retinal dystrophy, arrhythmia, and immunodeficiency in diverse ancestries. Hum Mutat. 2021;42(8):969-977doi: 10.1002/humu.24220.
Forrest, I. S., Chaudhary, K., Vy, H. M. T., Bafna, S., Kim, S., Won, H. H., Loos, R. J. F., Cho, J., Pasquale, L. R., Nadkarni, G. N., Rocheleau, G., & Do, R. (2021). Genetic pleiotropy of ERCC6 loss-of-function and deleterious missense variants links retinal dystrophy, arrhythmia, and immunodeficiency in diverse ancestries. Human mutation, 42(8), 969-977. https://doi.org/10.1002/humu.24220
Forrest, Iain S, et al. "Genetic pleiotropy of ERCC6 loss-of-function and deleterious missense variants links retinal dystrophy, arrhythmia, and immunodeficiency in diverse ancestries." Human mutation vol. 42,8 (2021): 969-977. doi: https://doi.org/10.1002/humu.24220
Forrest IS, Chaudhary K, Vy HMT, Bafna S, Kim S, Won HH, Loos RJF, Cho J, Pasquale LR, Nadkarni GN, Rocheleau G, Do R. Genetic pleiotropy of ERCC6 loss-of-function and deleterious missense variants links retinal dystrophy, arrhythmia, and immunodeficiency in diverse ancestries. Hum Mutat. 2021 Aug;42(8):969-977. doi: 10.1002/humu.24220. Epub 2021 May 31. PMID: 34005834; PMCID: PMC8295228.
Copy Download .nbib Format: NLM
An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy.

The Journal of experimental medicine

Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, Miles B, Farias E, Mezei M, Nobre AR, Singh D, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA.
PMID: 34812843
J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20210836. Epub 2021 Nov 23.

We describe the discovery of an agonist of the nuclear receptor NR2F1 that specifically activates dormancy programs in malignant cells. The agonist led to a self-regulated increase in NR2F1 mRNA and protein and downstream transcription of a novel dormancy...

Cite
Khalil BD, Sanchez R, Rahman T, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2021;219(1)doi: 10.1084/jem.20210836.
Khalil, B. D., Sanchez, R., Rahman, T., Rodriguez-Tirado, C., Moritsch, S., Martinez, A. R., Miles, B., Farias, E., Mezei, M., Nobre, A. R., Singh, D., Kale, N., Sproll, K. C., Sosa, M. S., & Aguirre-Ghiso, J. A. (2022). An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. The Journal of experimental medicine, 219(1), . https://doi.org/10.1084/jem.20210836
Khalil, Bassem D, et al. "An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy." The Journal of experimental medicine vol. 219,1 (2022). doi: https://doi.org/10.1084/jem.20210836
Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, Miles B, Farias E, Mezei M, Nobre AR, Singh D, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022 Jan 03;219(1). doi: 10.1084/jem.20210836. Epub 2021 Nov 23. PMID: 34812843; PMCID: PMC8614154.
Copy Download .nbib Format: NLM
Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single cell RNA sequencing.

bioRxiv : the preprint server for biology

Cohen P, DeGrace EJ, Danziger O, Patel RS, Rosenberg BR.
PMID: 34845443
bioRxiv. 2021 Nov 24; doi: 10.1101/2021.11.22.469642.

Single cell RNA sequencing (scRNAseq) studies have provided critical insight into the pathogenesis of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), the causative agent of COronaVIrus Disease 2019 (COVID-19). scRNAseq workflows are generally designed for the detection and quantification...

Cite
Cohen P, DeGrace EJ, Danziger O, et al. Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single cell RNA sequencing. bioRxiv. 2021;doi: 10.1101/2021.11.22.469642.
Cohen, P., DeGrace, E. J., Danziger, O., Patel, R. S., & Rosenberg, B. R. (2021). Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single cell RNA sequencing. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.11.22.469642
Cohen, Phillip, et al. "Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single cell RNA sequencing." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.11.22.469642
Cohen P, DeGrace EJ, Danziger O, Patel RS, Rosenberg BR. Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single cell RNA sequencing. bioRxiv. 2021 Nov 24; doi: 10.1101/2021.11.22.469642. PMID: 34845443; PMCID: PMC8629185.
Copy Download .nbib Format: NLM
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity.

Cancer discovery

Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigí M, Campisi M, Hong D, Thai TC, Piel B, Han S, Reinhold BB, Duke-Cohan JS, Poitras MJ, Taus LJ, Lizotte PH, Portell A, Quadros V, Santucci AD, Murayama T, Cañadas I, Kitajima S, Akitsu A, Fridrikh M, Watanabe H, Reardon B, Gokhale PC, Paweletz CP, Awad MM, Van Allen EM, Lako A, Wang XT, Chen B, Hong F, Sholl LM, Tolstorukov MY, Pfaff K, Jänne PA, Gjini E, Edwards R, Rodig S, Reinherz EL, Oser MG, Barbie DA.
PMID: 33707236
Cancer Discov. 2021 Aug;11(8):1952-1969. doi: 10.1158/2159-8290.CD-20-0913. Epub 2021 Mar 11.

Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we discover that a distinct subset of SCLC uniquely upregulates...

Cite
Mahadevan NR, Knelson EH, Wolff JO, et al. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021;11(8):1952-1969doi: 10.1158/2159-8290.CD-20-0913.
Mahadevan, N. R., Knelson, E. H., Wolff, J. O., Vajdi, A., Saigí, M., Campisi, M., Hong, D., Thai, T. C., Piel, B., Han, S., Reinhold, B. B., Duke-Cohan, J. S., Poitras, M. J., Taus, L. J., Lizotte, P. H., Portell, A., Quadros, V., Santucci, A. D., Murayama, T., Cañadas, I., Kitajima, S., Akitsu, A., Fridrikh, M., Watanabe, H., Reardon, B., Gokhale, P. C., Paweletz, C. P., Awad, M. M., Van Allen, E. M., Lako, A., Wang, X. T., Chen, B., Hong, F., Sholl, L. M., Tolstorukov, M. Y., Pfaff, K., Jänne, P. A., Gjini, E., Edwards, R., Rodig, S., Reinherz, E. L., Oser, M. G., & Barbie, D. A. (2021). Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer discovery, 11(8), 1952-1969. https://doi.org/10.1158/2159-8290.CD-20-0913
Mahadevan, Navin R, et al. "Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity." Cancer discovery vol. 11,8 (2021): 1952-1969. doi: https://doi.org/10.1158/2159-8290.CD-20-0913
Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigí M, Campisi M, Hong D, Thai TC, Piel B, Han S, Reinhold BB, Duke-Cohan JS, Poitras MJ, Taus LJ, Lizotte PH, Portell A, Quadros V, Santucci AD, Murayama T, Cañadas I, Kitajima S, Akitsu A, Fridrikh M, Watanabe H, Reardon B, Gokhale PC, Paweletz CP, Awad MM, Van Allen EM, Lako A, Wang XT, Chen B, Hong F, Sholl LM, Tolstorukov MY, Pfaff K, Jänne PA, Gjini E, Edwards R, Rodig S, Reinherz EL, Oser MG, Barbie DA. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 Aug;11(8):1952-1969. doi: 10.1158/2159-8290.CD-20-0913. Epub 2021 Mar 11. PMID: 33707236; PMCID: PMC8338750.
Copy Download .nbib Format: NLM
Breast Cancer, Alzheimer's Disease, and .

Journal of Alzheimer's disease reports

Lehrer S, Rheinstein PH.
PMID: 33681716
J Alzheimers Dis Rep. 2021 Jan 20;5(1):49-53. doi: 10.3233/ADR-200266.

BACKGROUND: Cognitive problems are common in breast cancer patients. The apolipoprotein E4 (OBJECTIVE: To further evaluate the effects of the METHODS: Our analysis included all subjects with invasive breast cancer. Single nucleotide polymorphism (SNP) data for rs 429358 and...

Cite
Lehrer S, Rheinstein PH. Breast Cancer, Alzheimer's Disease, and . J Alzheimers Dis Rep. 2021;5(1):49-53doi: 10.3233/ADR-200266.
Lehrer, S., & Rheinstein, P. H. (2021). Breast Cancer, Alzheimer's Disease, and . Journal of Alzheimer's disease reports, 5(1), 49-53. https://doi.org/10.3233/ADR-200266
Lehrer, Steven, and Rheinstein, Peter H. "Breast Cancer, Alzheimer's Disease, and ." Journal of Alzheimer's disease reports vol. 5,1 (2021): 49-53. doi: https://doi.org/10.3233/ADR-200266
Lehrer S, Rheinstein PH. Breast Cancer, Alzheimer's Disease, and . J Alzheimers Dis Rep. 2021 Jan 20;5(1):49-53. doi: 10.3233/ADR-200266. PMID: 33681716; PMCID: PMC7902990.
Copy Download .nbib Format: NLM
Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells.

Nature aging

Navarro E, Udine E, de Paiva Lopes K, Parks M, Riboldi G, Schilder BM, Humphrey J, Snijders GJL, Vialle RA, Zhuang M, Sikder T, Argyrou C, Allan A, Chao MJ, Farrell K, Henderson B, Simon S, Raymond D, Elango S, Ortega RA, Shanker V, Swan M, Zhu CW, Ramdhani R, Walker RH, Tse W, Sano M, Pereira AC, Ahfeldt T, Goate AM, Bressman S, Crary JF, de Witte L, Frucht S, Saunders-Pullman R, Raj T.
PMID: 35005630
Nat Aging. 2021 Sep;1(9):850-863. doi: 10.1038/s43587-021-00110-x. Epub 2021 Sep 14.

An increasing number of identified Parkinson's disease (PD) risk loci contain genes highly expressed in innate immune cells, yet their role in pathology is not understood. We hypothesize that PD susceptibility genes modulate disease risk by influencing gene expression...

Cite
Navarro E, Udine E, de Paiva Lopes K, et al. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells. Nat Aging. 2021;1(9):850-863doi: 10.1038/s43587-021-00110-x.
Navarro, E., Udine, E., de Paiva Lopes, K., Parks, M., Riboldi, G., Schilder, B. M., Humphrey, J., Snijders, G. J. L., Vialle, R. A., Zhuang, M., Sikder, T., Argyrou, C., Allan, A., Chao, M. J., Farrell, K., Henderson, B., Simon, S., Raymond, D., Elango, S., Ortega, R. A., Shanker, V., Swan, M., Zhu, C. W., Ramdhani, R., Walker, R. H., Tse, W., Sano, M., Pereira, A. C., Ahfeldt, T., Goate, A. M., Bressman, S., Crary, J. F., de Witte, L., Frucht, S., Saunders-Pullman, R., & Raj, T. (2021). Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells. Nature aging, 1(9), 850-863. https://doi.org/10.1038/s43587-021-00110-x
Navarro, Elisa, et al. "Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells." Nature aging vol. 1,9 (2021): 850-863. doi: https://doi.org/10.1038/s43587-021-00110-x
Navarro E, Udine E, de Paiva Lopes K, Parks M, Riboldi G, Schilder BM, Humphrey J, Snijders GJL, Vialle RA, Zhuang M, Sikder T, Argyrou C, Allan A, Chao MJ, Farrell K, Henderson B, Simon S, Raymond D, Elango S, Ortega RA, Shanker V, Swan M, Zhu CW, Ramdhani R, Walker RH, Tse W, Sano M, Pereira AC, Ahfeldt T, Goate AM, Bressman S, Crary JF, de Witte L, Frucht S, Saunders-Pullman R, Raj T. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson's disease myeloid cells. Nat Aging. 2021 Sep;1(9):850-863. doi: 10.1038/s43587-021-00110-x. Epub 2021 Sep 14. PMID: 35005630; PMCID: PMC8728893.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries